AZ 8037
Alternative Names: AZ’8037Latest Information Update: 29 Jul 2022
At a glance
- Originator AstraZeneca
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer
Most Recent Events
- 03 Jun 2022 Preclinical trials in Colorectal cancer in United Kingdom (unspecified route)